Applying GHK-Cu topically immediately after microneedling is a common clinical practice because barrier disruption improves penetration dramatically
Food and Drug Administration (FDA) approved the use of Wegovy (Semaglutide) for treating weight loss
Epsilon glutathione transferases possess a unique class-conserved subunit interface motif that directly interacts with glutathione in the active site
It may lead to a reduction in muscle volume, which is a significant drawback, especially considering the importance of muscle in maintaining a healthy body composition and metabolism
Increase of 44 blood metabolites and decrease of 2 during fasting We employed non-targeted, comprehensive analysis of whole blood, plasma, and RBC metabolites using the software, MZmine 2 18 for metabolite identification
Semaglutide reduced systolic blood pressure by 3.3 mm Hg, high-sensitivity C-reactive protein by 37.8%, and improved lipid profilesall achieved on top of high baseline rates of evidence-based cardiovascular therapies (90% on statins, 86% on antiplatelet agents).[1] These pleiotropic effects likely contribute to cardiovascular risk reduction through mechanisms distinct from adiposity changes, supporting the reconceptualization of GLP-1 receptor agonists as cardiovascular disease-modifying agents rather than simply weight-loss medications
